Gattefossé

Abstract Liver diseases—encompassing hepatitis, liver fibrosis, fatty liver, and hepatocellular carcinoma—constitute a formidable global health challenge. Existing treatments are often...

This poster was presented by Gattefossé at CRS 2025, the Annual Meeting and Exposition conference 2025 in Philadelphia, PA: Introduction...

Abstract Oral administration of proteins and peptides is extremely difficult due to the nature of the digestive system, which is...

Abstract Solidification of liquid self-nanoemulsifying drug delivery systems (L-SNEDDS) is commonly used to avoid formulation leakage during storage. However, traditional...

Abstract Tacrolimus (TAC), a calcineurin inhibitor used topically for T-cell-mediated skin diseases, faces challenges due to poor solubility and limited...

This year CPHI Europe opens its doors in Frankfurt at Messe Frankfurt. From 28th to 30th October you can have...

A landmark investment for the Group’s international expansion PRESS RELEASE Lyon, France - September 25, 2025 - Gattefossé, a leading provider...

Abstract Poor bioavailability and systemic toxicity restrict the oral administration of chemotherapeutic agents such as exemestane (EXM) and quercetin (QUR)....

Abstract Background/Objective Drug delivery to the gastrointestinal tract (GIT) has become very important for the local treatment of digestive diseases...

Abstract This work outlines the formulation and characterization of Fenticonazoleloaded LeciPlex (FCN-LPX), adopting a simple blending technique for the eradication...